It often takes many years before a new active compound from basic research hits the market as a drug. In order to accelerate this process, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Saarland...
In the coronavirus pandemic, older people are particularly at risk from severe courses of COVID-19. However, other infectious diseases also affect them more than younger people. On the occasion of the International Day...
EMBL and the six Helmholtz Centers of the Research Field Health (Helmholtz Health) are expanding their collaboration. The two research organisations are cooperating to expand the frontiers of health research and advance...
On 9 September 2021, the 13th TWINCORE Symposium took place. This year, too, the event was held online due to corona. Nevertheless, the webinar was a great success and attracted even more viewers than last year.
...
New antibiotics are urgently needed in the fight against multi-resistant bacteria. The recently discovered darobactin is a potential candidate with resistance-breaking properties. This substance shows very good...
Data Scientists are in demand on the job market: all 18 Helmholtz Centers have already advertised several positions calling for skills in AI methods in 2021.
Increasingly insensitive to standard drugs: Multi-resistant pathogens are spreading worldwide and even in the near future could threaten the safe treatment of deadly infectious diseases. However, the urgent demand for...
The Alexander von Humboldt Foundation has selected Prof Claus-Michael Lehr as a scout within the Henriette Herz Programme.This award allows him to select three young scientific talents from abroad who will work at HIPS...
The oral cavity germ Fusobacterium nucleatum is known to speed up the growth of human carcinomas, for example in the intestine or breast. In a joint study, the Helmholtz Institute for RNA-based Infection Research...
